TY - GEN
T1 - Secretome and Ramiprilat Effects on Endothelial Progenitor Cells Proliferation in Chronic Coronary Syndrome Patient
AU - Her Oktaviono, Yudi
AU - Sandra, Ferry
AU - Lefi, Achmad
AU - Pramudita Budianto, Christian
N1 - Publisher Copyright:
© 2020 ACM.
PY - 2020/11/6
Y1 - 2020/11/6
N2 - It is known, that patients with chronic coronary syndrome (CCS) have lower endothelial progenitor cells (EPC) levels compared with healthy people. Secretome is a paracrine product from human umbilical cord blood mesenchymal stem cells (hUCB-MSC) that contains growth factors that enhanced the neovascularization and angiogenesis. Ramiprilat is an active form of ramipril which acts as an angiotensisn-converting enzyme inhibitor (ACE-I). Ramipril has been shown to have an effect on EPC proliferation. The effect of secretome alone or combination with ramiprilat is not yet elucidated. This study aimed to identify the effect of secretome compared with ramiprilat on EPC proliferation. The EPC was collected from a CCS person and cultered in stemline II medium for seven days. Cultured EPC were then divided into 8 groups of control, various doses of secretome (2, 10, and 20%), ramiprilat 10 μmol, and combination of various doses of secretome and ramiprilat. Three days after the treatement, the EPC proliferation measured by MTT assay in 96-well plated. The result of this study shown the higher the dose of secretome (2,10, and 20%) increase the proliferation of EPC better than ramiprilat (0.7128; 1.2417; 1.585 OD vs 0.7 OD; p<0.001). in conclusion secretome works in dose-dependent manner, the higher the concentration of secretome, the higher the EPC proliferation.
AB - It is known, that patients with chronic coronary syndrome (CCS) have lower endothelial progenitor cells (EPC) levels compared with healthy people. Secretome is a paracrine product from human umbilical cord blood mesenchymal stem cells (hUCB-MSC) that contains growth factors that enhanced the neovascularization and angiogenesis. Ramiprilat is an active form of ramipril which acts as an angiotensisn-converting enzyme inhibitor (ACE-I). Ramipril has been shown to have an effect on EPC proliferation. The effect of secretome alone or combination with ramiprilat is not yet elucidated. This study aimed to identify the effect of secretome compared with ramiprilat on EPC proliferation. The EPC was collected from a CCS person and cultered in stemline II medium for seven days. Cultured EPC were then divided into 8 groups of control, various doses of secretome (2, 10, and 20%), ramiprilat 10 μmol, and combination of various doses of secretome and ramiprilat. Three days after the treatement, the EPC proliferation measured by MTT assay in 96-well plated. The result of this study shown the higher the dose of secretome (2,10, and 20%) increase the proliferation of EPC better than ramiprilat (0.7128; 1.2417; 1.585 OD vs 0.7 OD; p<0.001). in conclusion secretome works in dose-dependent manner, the higher the concentration of secretome, the higher the EPC proliferation.
KW - Endothelial progenitor cells
KW - human umbilical cord blood - mesenchymal stem cells (hUCB-MSC)
KW - proliferation
KW - ramiprilat
KW - secretome
UR - http://www.scopus.com/inward/record.url?scp=85103828610&partnerID=8YFLogxK
U2 - 10.1145/3444884.3444910
DO - 10.1145/3444884.3444910
M3 - Conference contribution
AN - SCOPUS:85103828610
T3 - ACM International Conference Proceeding Series
SP - 136
EP - 139
BT - Proceedings of 2020 7th International Conference on Biomedical and Bioinformatics Engineering, ICBBE 2020
PB - Association for Computing Machinery
T2 - 7th International Conference on Biomedical and Bioinformatics Engineering, ICBBE 2020
Y2 - 6 November 2020 through 9 November 2020
ER -
